Identification
- Summary
Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.
- Generic Name
- Canrenoic acid
- DrugBank Accession Number
- DB09015
- Background
Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Canrenoic acid (DB09015)
- Weight
- Average: 358.478
Monoisotopic: 358.214409446 - Chemical Formula
- C22H30O4
- Synonyms
- ácido canrenoico
- Canrenoate
- Canrenoic acid
- External IDs
- MF 465a
- SC 14266
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Edema •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Edema caused by secondary aldosteronism •••••••••••• •••••••••• ••••••• ••• ••••••••• •••••••••• ••••••••• ••••••••• ••••••• ••••••• •••••• Management of Essential arterial hypertension •••••••••••• •••••••••••• •••••••• •• ••••• ••••••••• •••••••••• ••••••• ••• •••••••• Treatment of High blood pressure (hypertension) •••••••••••• •••••••••• •• •• •••••••••• •• ••••• •••••••••• ••••••• •••••••• •••••••••• ••••••• ••• ••••••••• •••••••••• ••••••••• ••••••••• ••••••• ••••••• •••••• Management of Primary hyperaldosteronism •••••••••••• •••••••••• ••••••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Canrenoic acid may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy. Acebutolol The risk or severity of hyperkalemia can be increased when Acebutolol is combined with Canrenoic acid. Aceclofenac The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Canrenoic acid. Acemetacin The therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Acemetacin. Acetaminophen Canrenoic acid may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Potassium canrenoate M671F9NLEA 2181-04-6 JTZQCHFUGHIPDF-RYVBEKKQSA-M - International/Other Brands
- Soludactone (Pfizer)
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image KADIUR Potassium canrenoate (50 mg) + Buthiazide (5 mg) Tablet Oral Neopharmed Gentili S.P.A. 2014-07-08 2021-04-20 Italy 
KADIUR Potassium canrenoate (50 MG) + Buthiazide (5 MG) Tablet, coated Oral Neopharmed Gentili S.P.A. 2014-07-08 Not applicable Italy KADIUR Potassium canrenoate (50 MG) + Buthiazide (5 MG) Tablet, coated Oral Neopharmed Gentili S.P.A. 2014-07-08 Not applicable Italy
Categories
- ATC Codes
- C03DA02 — Potassium canrenoate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Androstane steroids
- Direct Parent
- Androgens and derivatives
- Alternative Parents
- Steroid acids / 3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Tertiary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
- Substituents
- 17-hydroxysteroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Androgen-skeleton / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Cyclic alcohol / Cyclic ketone
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- monocarboxylic acid, 3-oxo Delta(4)-steroid, steroid acid (CHEBI:50156) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030154)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 87UG89VA9K
- CAS number
- 4138-96-9
- InChI Key
- PBKZPPIHUVSDNM-WNHSNXHDSA-N
- InChI
- InChI=1S/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1
- IUPAC Name
- 3-[(1S,2R,10R,11S,14R,15S)-14-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-6,8-dien-14-yl]propanoic acid
- SMILES
- [H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C
References
- Synthesis Reference
U.S. Patent 2,900,383.
- General References
- Not Available
- External Links
- PubChem Compound
- 656615
- PubChem Substance
- 310264973
- ChemSpider
- 570976
- 618970
- ChEBI
- 50156
- ChEMBL
- CHEMBL1616951
- ZINC
- ZINC000003938750
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Potassium_canrenoate
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Recruiting Treatment Acute Heart Failure (AHF) / Diuretics Drug Reactions 1 4 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID-19 Pneumonia 1 3 Completed Treatment ST Segment Elevation Myocardial Infarction (STEMI) 1 2 Not Yet Recruiting Treatment Acute Respiratory Distress Syndrome Caused by COVID-19 / Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Prevention Brain Dead Organ Donors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Parenteral 200 mg/10ml Tablet, film coated Oral 100 MG Tablet Oral Tablet, coated Oral Tablet Oral 100 MG Tablet Oral 25 MG Tablet Oral 50 MG Tablet, film coated Oral 200 MG Injection, powder, for solution Intravenous 200 MG/2ML Solution Intravenous 200 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 165 U.S. Patent 2,900,383. - Predicted Properties
Property Value Source Water Solubility 0.0442 mg/mL ALOGPS logP 2.73 ALOGPS logP 2.93 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 4.48 Chemaxon pKa (Strongest Basic) -3.1 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 74.6 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 100.98 m3·mol-1 Chemaxon Polarizability 40.44 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-006x-0009000000-511e340f4a8d02e244cf Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0bt9-0009000000-ce495d0a67abb1b12384 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-00dl-0379000000-7f1becda2d3dfb2d2cf9 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0bt9-1009000000-2b0728e86dbfea404ba9 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-05n0-0079000000-960402ae7630a58298be Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-001a-3962000000-7ac607f87ce07554f42e Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 187.5247 predictedDeepCCS 1.0 (2019) [M+H]+ 189.4201 predictedDeepCCS 1.0 (2019) [M+Na]+ 196.53328 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2014 17:28 / Updated at February 21, 2024 02:33